Biotron Ltd (BITRF) 0.0600 $BITRF
Biotron Phase 2 Hepatitis C Trial Success
PR Newswire - Thu Mar 17, 5:00AM CDT
Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.
BIT: 16.90 (-0.04)
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 6.46 (+0.14), CLDX: 4.77 (+0.11), BMY: 76.47 (+1.41)
Global Prostate Cancer Pipeline Review 2015 - Featuring 150+ Comapnies
M2 - Tue Nov 03, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/j8c7fb/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Prostate Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Prostate Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Prostate Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Prostate Cancer - Pipeline Products under Development by Companies 5 Prostate Cancer Companies and Product Overview 6 Prostate Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 150 Companies Featured - 3D Biomatrix, LLC - A&G Pharmaceutical, Inc. - Abbott Diagnostics - Abnova Corporation - AccuTech, LLC - Advanced Marker Discovery, S.L. - Affinimark Technologies, Inc. - Almac Diagnostics Limited - AltheaDx, Inc. - Ambrilia Biopharma Inc. - Andro Diagnostics - Arno Therapeutics, Inc. - AroCell AB - Arrayit Diagnostics, Inc. - Bayer HealthCare AG - Baylor College of Medicine - Beckman Coulter, Inc. - Biocare Medical LLC - Biocept, Inc. - Biocrates Life Sciences AG - BioMark Diagnostics Inc. - BioMark Technologies Inc. - bioMerieux S.A. - BioRap Technologies Ltd. - Biosceptre (Aust) Pty Ltd - Biotron Limited - Blondin Bioscience, LLC - Caldera Health Limited - Cancer Genetics, Inc. - Cancer Research Technology Limited - Caprion Inc. - Caris Life Sciences, Inc. - Cellanyx Diagnostics, Inc. - CellMax Life - Cellmid Limited For more information visit http://www.researchandmarkets.com/research/j8...ate_cancer
IDGX: (), BIOC: 0.67 (+0.04), CGIX: 2.07 (+0.02)
Biotron Limited - Product Pipeline Review - 2014
M2 - Mon Jun 08, 8:34AM CDT
Product Pipeline Review - 2014
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 13.01 (+0.09), ARWR: 6.01 (+0.26), ACHN: 8.40 (+0.01), CNAT: 2.34 (+0.01), ANAC: 99.06 (-0.14), ABBV: 64.90 (+0.45), BMY: 76.47 (+1.41), CELGZ: 1.19 (+0.03)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 29.96 (+0.99), JNJ: 124.77 (-0.38), UTHR: 113.20 (+0.75), MRK: 58.60 (+0.24), NNVC: 1.74 (+0.04), GSK: 45.12 (+0.96)
Biotron Phase 2 Hepatitis C Trial Success
PR Newswire - Thu Mar 17, 5:00AM CDT
Biotron Limited (ASX: BIT) confirms positive outcomes from its Phase 2 study of its first-in-class antiviral drug BIT225.
BIT: 16.90 (-0.04)
HIV / AIDS Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/zx8ggt/hiv_aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDSand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HIV / AIDSOverview - Therapeutics Development - Pipeline Products for HIV / AIDS - Overview - Pipeline Products for HIV / AIDS - Comparative Analysis - HIV / AIDS - Therapeutics under Development by Companies - HIV / AIDS - Therapeutics under Investigation by Universities/Institutes - HIV / AIDS - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - HIV / AIDS - Products under Development by Companies - HIV / AIDS - Products under Investigation by Universities/Institutes - HIV / AIDS - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Abivax S.A. - Adaptimmune Limited - AiCuris GmbH & Co. KG - Akshaya Bio Inc. - Altor BioScience Corporation - AltraVax Inc. - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Amplyx Pharmaceuticals, Inc. - Antigen Express, Inc. - Aphios Corporation - Apotex, Inc. - Argos Therapeutics, Inc. - Arno Therapeutics, Inc. - Avexa Limited - BCI Pharma - Beth Israel Deaconess Medical Center, Inc. - BioClonetics Immunotherapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - BioSource Pharm, Inc. - Biotron Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - C4X Discovery Limited - Calimmune, Inc. - Celldex Therapeutics, Inc. - Chipscreen Biosciences Ltd - Cocrystal Pharma, Inc. - CompleGen, Inc. - Critical Outcome Technologies Inc. - CureVac GmbH - Cytodyn Inc. For more information visit http://www.researchandmarkets.com/research/zx8ggt/hiv_aids
ARGS: 6.46 (+0.14), CLDX: 4.77 (+0.11), BMY: 76.47 (+1.41)
Global Prostate Cancer Pipeline Review 2015 - Featuring 150+ Comapnies
M2 - Tue Nov 03, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/j8c7fb/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Prostate Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Prostate Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Prostate Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Prostate Cancer - Pipeline Products under Development by Companies 5 Prostate Cancer Companies and Product Overview 6 Prostate Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 150 Companies Featured - 3D Biomatrix, LLC - A&G Pharmaceutical, Inc. - Abbott Diagnostics - Abnova Corporation - AccuTech, LLC - Advanced Marker Discovery, S.L. - Affinimark Technologies, Inc. - Almac Diagnostics Limited - AltheaDx, Inc. - Ambrilia Biopharma Inc. - Andro Diagnostics - Arno Therapeutics, Inc. - AroCell AB - Arrayit Diagnostics, Inc. - Bayer HealthCare AG - Baylor College of Medicine - Beckman Coulter, Inc. - Biocare Medical LLC - Biocept, Inc. - Biocrates Life Sciences AG - BioMark Diagnostics Inc. - BioMark Technologies Inc. - bioMerieux S.A. - BioRap Technologies Ltd. - Biosceptre (Aust) Pty Ltd - Biotron Limited - Blondin Bioscience, LLC - Caldera Health Limited - Cancer Genetics, Inc. - Cancer Research Technology Limited - Caprion Inc. - Caris Life Sciences, Inc. - Cellanyx Diagnostics, Inc. - CellMax Life - Cellmid Limited For more information visit http://www.researchandmarkets.com/research/j8...ate_cancer
IDGX: (), BIOC: 0.67 (+0.04), CGIX: 2.07 (+0.02)
Biotron Limited - Product Pipeline Review - 2014
M2 - Mon Jun 08, 8:34AM CDT
Product Pipeline Review - 2014
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 13.01 (+0.09), ARWR: 6.01 (+0.26), ACHN: 8.40 (+0.01), CNAT: 2.34 (+0.01), ANAC: 99.06 (-0.14), ABBV: 64.90 (+0.45), BMY: 76.47 (+1.41), CELGZ: 1.19 (+0.03)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 29.96 (+0.99), JNJ: 124.77 (-0.38), UTHR: 113.20 (+0.75), MRK: 58.60 (+0.24), NNVC: 1.74 (+0.04), GSK: 45.12 (+0.96)
